Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 7/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25936773 | 0.97 | KCNJ1 (0.39) | KCNJ1SIGMAR1S1PR1KCNH2OPRK1 | |
| SCHEMBL17986201 | 0.91 | KCNJ1 (0.45) | KCNJ1SIGMAR1S1PR1KCNH2OPRK1 | |
| SCHEMBL3769255 | 0.88 | KCNJ1 (0.46) | KCNJ1SIGMAR1S1PR1KCNH2OPRK1 | |
| SCHEMBL3249763 | 0.88 | KCNJ1 (0.46) | KCNJ1SIGMAR1S1PR1KCNH2OPRK1 | |
| SCHEMBL13014054 | 0.83 | KCNJ1 (0.45) | KCNJ1SIGMAR1KCNH2OPRK1HRH3 | |
| SCHEMBL13014130 | 0.83 | KCNJ1 (0.45) | KCNJ1SIGMAR1KCNH2OPRK1HRH3 | |
| SCHEMBL7943880 | 0.82 | KCNJ1 (0.40) | KCNJ1SIGMAR1S1PR1KCNH2OPRK1 | |
| SCHEMBL16631744 | 0.81 | KCNJ1 (0.45) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL17986129 | 0.81 | KCNJ1 (0.45) | KCNJ1SIGMAR1KCNH2CCR2HRH3 | |
| SCHEMBL18021193 | 0.80 | SIGMAR1 (0.45) | KCNJ1SIGMAR1KCNH2OPRK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248854-A1 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248854-A1 | METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY | CD4, PTMS, TAC3 | KCNJ1 2736/4885SIGMAR1 4708/4885S1PR1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.